Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-3150 (esaxerenone) plus ARB/ACE inhibitor in hypertensive patients with moderate kidney dysfunction
jRCT2080223233Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of esaxerenone in hypertension (HTN), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Change in sitting systolic blood pressure from baseline, Change in sitting diastolic blood pressure from baseline and 1 more. Started Jun 2016; status: completed.
02
Drugs
esaxerenone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on jRCT2080223233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223233.